Table 2.
SM reported in studies on selected groups of pediatric patients with mastocytosis.
| Reference | Number of Patients | Number of SM Patients (%) | Form of SM |
|---|---|---|---|
| Bodemer C. et al. (2010) [19] | 65 | 1 (1.5) | no data reported |
| Alvarez-Twose I. et al. (2012) [7] | 111 | 2 (1.8) | 1 ISM, 1 WDSM ** |
| Lange M. et al. (2013) [12] | 101 | 1 (1) | 1 ISM |
| Méni C. et al. (2015) [8] * | 1747 | 16 (0.9) | 4 ISM; 8 MCS; 4 MCL |
| Carter M. et al. (2015) [9] | 108 | 18 (16.6) | 18 ISM |
| Matito A. et al. (2015) [125] | 42 | 2 (4.8) | 2 WDSM ** |
| Méni C. et al. (2018) [16] | 53 | 1 (1.9) | 1 ISM |
| Carter M. et al. (2018) [10] | 65 | 23 (35.4) | 23 ISM |
| Czarny J. et al. (2020) [11] *** | 32 | 4 (12.5) | 1 SSM, 3 ISM |
SM—systemic mastocytosis; ISM—indolent systemic mastocytosis; WDSM—well-differentiated SM; MCS—mast cell sarcoma; MCL—mast cell leukemia; * a systematic review of cases published between 1950 and 2014; ** the exact WHO type of SM was not provided; *** only children with cutaneous involvement >50% of body surface area were included.